Can-Fite BioPharma Ltd.(CANF)

$3.40—Earnings · Aug 27

Chart

Can-Fite BioPharma Ltd.(CANF)

NYSE

$3.40—Earnings · Aug 27

Chart Studio

CANF(CANF)

CANF

Overview Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-0.33

Aug 27, 2026

Revenue Estimate

$300,000

FY2028E EPS$0.12

FY2029E EPS$0.39

Analyst Sentiment

Wall St. Consensus

Buy

4 analysts·Low coverage

Score

3 Buy (75%)1 Hold (25%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

375%

Hold

125%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$8.00

+135.3%

Consensus

$8.00

+135.3%

Bull

$8.00

+135.3%

12-Month Target Range4 analysts

$8.00$8.00$8.00

Current $3.40Consensus

Current Price

$3.40

Upside to Consensus

$4.60

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-86.35%

EPS—

FY2028

Rev+1145.18%

EPS—

FY2029

Rev+113.17%

EPS+225.00%

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$21M	$3M	$35M	$75M	$113M
Low	$21M	$3M	$35M	$75M	$113M
High	$21M	$3M	$35M	$75M	$113M
EBITDA Avg	$-21M	$-3M	$-35M	$-75M	$-113M
Low	$-21M	$-3M	$-35M	$-75M	$-113M
High	$-21M	$-3M	$-35M	$-75M	$-113M
EBIT Avg	$-21M	$-3M	$-35M	$-75M	$-113M
Low	$-21M	$-3M	$-35M	$-75M	$-113M
High	$-21M	$-3M	$-35M	$-75M	$-113M
Net Income Avg	$-84M	$-33M	$15M	$48M	$79M
Low	$-84M	$-33M	$15M	$48M	$79M
High	$-84M	$-33M	$15M	$48M	$79M
EPS Avg	$-0.68	$-0.27	$0.12	$0.39	$0.64
Low	$-0.68	$-0.27	$0.12	$0.39	$0.64
High	$-0.68	$-0.27	$0.12	$0.39	$0.64
Analysts (Rev / EPS)	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027	Q1 2028	Q2 2028
Revenue Avg	$218,333	$140,000	$266,667	$133,333	$250,000	$300,000	$500,000	$200,000
Low	$218,333	$140,000	$266,667	$133,333	$250,000	$300,000	$500,000	$200,000
High	$218,333	$140,000	$266,667	$133,333	$250,000	$300,000	$500,000	$200,000
EBITDA Avg	$-218,333	$-140,000	$-266,667	$-133,333	$-250,000	$-300,000	$-500,000	$-200,000
Low	$-218,333	$-140,000	$-266,667	$-133,333	$-250,000	$-300,000	$-500,000	$-200,000
High	$-218,333	$-140,000	$-266,667	$-133,333	$-250,000	$-300,000	$-500,000	$-200,000
EBIT Avg	$-218,333	$-140,000	$-266,667	$-133,333	$-250,000	$-300,000	$-500,000	$-200,000
Low	$-218,333	$-140,000	$-266,667	$-133,333	$-250,000	$-300,000	$-500,000	$-200,000
High	$-218,333	$-140,000	$-266,667	$-133,333	$-250,000	$-300,000	$-500,000	$-200,000
Net Income Avg	$-10.02B	$-4.53B	$-10.99B	$-9.05B	$-4.74B	$-5.82B	$-5.90B	$-4.59B
Low	$-10.02B	$-4.53B	$-10.99B	$-9.05B	$-4.74B	$-5.82B	$-5.90B	$-4.59B
High	$-10.02B	$-4.53B	$-10.99B	$-9.05B	$-4.74B	$-5.82B	$-5.90B	$-4.59B
EPS Avg	$-31.00	$-14.00	$-34.00	$-28.00	$-14.67	$-18.00	$-18.26	$-14.19
Low	$-31.00	$-14.00	$-34.00	$-28.00	$-14.67	$-18.00	$-18.26	$-14.19
High	$-31.00	$-14.00	$-34.00	$-28.00	$-14.67	$-18.00	$-18.26	$-14.19
Analysts (Rev / EPS)	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

Jul 2, 2026H.C. Wainwright

Can-Fite BioPharma (CANF) PT Raised to $8 at H.C. WainwrightMember Login

Target:$8.00

+72.8%from $4.63

May 12, 2026H.C. Wainwright

Can-Fite BioPharma target adjusted to $5 from $2.50 at H.C. Wainwright

Target:$5.00

+48.8%from $3.36

Apr 15, 2025Industrial Alliance Securities

Can-Fite price target lowered to $4.50 from $12 at Alliance Global Partners

Target:$4.50

-85.7%from $31.40

Jul 17, 2024EF Hutton

Can-Fite BioPharma initiated with a Buy at EF Hutton

Target:$10.00

-86.3%from $73.20

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance